drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (biologic)
drug_description
A recombinant anti-EGFR human/murine chimeric IgG1 monoclonal antibody (cetuximab biosimilar candidate) given as a single IV dose; binds EGFR (ErbB1/HER1), blocks EGF/TGF-α binding and receptor activation, promotes receptor internalization, inhibits RAS–RAF–MEK–ERK and PI3K–AKT signaling, and can mediate ADCC via its IgG1 Fc.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Monoclonal, Chimeric
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody targeting EGFR (ErbB1/HER1); competitively blocks EGF/TGF-α binding, prevents receptor activation and promotes internalization, thereby inhibiting downstream RAS–RAF–MEK–ERK and PI3K–AKT signaling to suppress tumor cell proliferation and survival; Fc region can engage Fcγ receptors to mediate ADCC.
drug_name
HLX05
nct_id_drug_ref
NCT06309043